Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs

Journal of the American Academy of Child & Adolescent Psychiatry - Tập 41 Số 9 - Trang 1026-1036 - 2002
R. E. Snyder1,2,3,4,5,6, Atilla Turgay1,2,3,4,5,6, Michael G. Aman1,2,3,4,5,6, Carin Binder1,2,3,4,5,6, Sandra Fisman1,2,3,4,5,6, ALLAN CARROLL1,2,3,4,5,6
1From the Royal University Hospital, Saskatoon, Saskatchewan, Canada (R.S.)
2Glenrose Rehabilitation Hospital, Edmonton, Alberta (A.C.). Members of the Risperidone Conduct Study Group and their affiliations are provided at the end of the text.
3Janssen-Ortho Inc., Toronto (C.B.)
4London Health Sciences, London, Ontario (S.F.)
5The Nisonger Center, Ohio State University, Columbus (M.A.)
6University of Toronto (A.T.)

Tóm tắt

Từ khóa


Tài liệu tham khảo

Allison, 1999, Antipsychotic-induced weight gain: a comprehensive research synthesis, Am J Psychiatry, 156, 1686, 10.1176/ajp.156.11.1686

Aman, 2002, Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence, Am J Psychiatry, 159, 1337, 10.1176/appi.ajp.159.8.1337

Aman, 1999, Atypical antipsychotics in persons with developmental disabilities, Ment Retard Dev Disabil Res Rev, 5, 253, 10.1002/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.0.CO;2-R

Aman, 1985, The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects, Am J Ment Defic, 89, 485

Aman, 1985, Psychometric characteristics of the Aberrant Behavior Checklist, Am J Ment Defic, 89, 492

Aman, 1996, The Nisonger CBRF: a child behavior rating form for children with developmental disabilities, Res Dev Disabil, 17, 41, 10.1016/0891-4222(95)00039-9

American Psychiatric Association, 1994

Benson, 1999, Disruptive behavior disorders in children with mental retardation, 559

Botteron, 1999, Disorders, symptoms, and their pharmacology, 183

Carman, 1995, Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis, Int Clin Psychopharmacol, 10, 207, 10.1097/00004850-199511000-00001

Chouinard, 1980, The Extrapyramidal Symptom Rating Scale (abstract), Can J Neurol Sci, 7, 233

Conner, 1998, Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment, J Child Adolesc Psychopharmacol, 8, 27, 10.1089/cap.1998.8.27

Conners, 1989

Delis, 1998

Dickson, 1999, Hyperprolactinemia and male sexual dysfunction, J Clin Psychiatry, 60, 125, 10.4088/JCP.v60n0210g

Dunn, 1981

Fava, 1997, Psychopharmacologic treatment of pathologic aggression, Psychiatr Clin North Am, 20, 427, 10.1016/S0193-953X(05)70321-X

Findling RL, Aman MG, Derivan A (2000a), Long-term safety and efficacy of risperidone in children with significant conduct problems and borderline IQ or mental retardation (poster). Presented at the 39th Annual American College of Neuropsychopharmacology meeting, San Juan, PR, December

Findling, 2000, A double-blind pilot study of risperidone in the treatment of conduct disorder, J Am Acad Child Adolesc Psychiatry, 39, 509, 10.1097/00004583-200004000-00021

Fraser, 1998, Beta-adrenergic blockers, 271

Gadow, 1994

Girouard, 1998, Étude de fidélité test-retest et accord inter-judges de la Grille D'Evaluation Comportementale Pour Enfants Nisonger (GECEN) [Test-retest and interjudge reliability study of the Grille of Comportemental Evaluation for Nisonger Children (GECEN)], Rev Francoph Defic Intel, 9, 127

Hardan, 1996, Case study: risperidone treatment of children and adolescents with developmental disorders, J Am Acad Child Adolesc Psychiatry, 35, 1551, 10.1097/00004583-199611000-00025

Kim, 1999, Risperidone and associated amenorrhea: a report of 5 cases, J Clin Psychiatry, 60, 315, 10.4088/JCP.v60n0509

Kleinberg, 1999, Prolactin levels and adverse events in patients treated with risperidone, J Clin Psychopharmacol, 19, 57, 10.1097/00004714-199902000-00011

National Institute of Mental Health, 1985, CGI (Clinical Global Impression) scale, Psychopharmacol Bull, 21, 39

Popli, 1998, Risperidone-induced galactorrhea associated with a prolactin elevation, Ann Clin Psychiatry, 10, 31, 10.3109/10401239809148815

Rojahn, 2001, The Behavior Problems Inventory: an instrument for the assessment of self injury, stereotyped behavior and aggression/destruction in individuals with developmental disabilities, J Autism Dev Disord, 31, 577, 10.1023/A:1013299028321

Schaal, 1994, Toward a functional analysis of drug treatment for behavioral problems of people with developmental disabilities, Am J Ment Retard, 99, 123

Shiwach, 1998, Prolactogenic effects of risperidone in male patients: a preliminary study, Acta Psychiatr Scand, 98, 81, 10.1111/j.1600-0447.1998.tb10046.x

Sparrow, 1984

Stark, 1988, Executive summary

Tassé, 1996, The Nisonger Child Behavior Rating Form: age and gender effects and norms, Res Dev Disabil, 17, 59, 10.1016/0891-4222(95)00037-2

Tassé, 2000, Comparing parent and teacher ratings of social competence and problem behaviors, Am J Ment Retard, 105, 252, 10.1352/0895-8017(2000)105<0252:CPATRO>2.0.CO;2

Tassé, 2000, Traduction et validation cannadienne-francaise du Nisonger Child Behavior Rating Form [Translation and validation of the French-Canadian Nisonger Child Behavior Rating Form], Can Psychol/Psychol Can, 44, 116, 10.1037/h0086861

Thorndike, 1986

Vanden Borre, 1993, Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study, Acta Psychiatr Scand, 87, 167, 10.1111/j.1600-0447.1993.tb03350.x

Wechsler, 1983

Wechsler, 1991

Weller, 1999, Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders, J Clin Psychiatry, 60, 5

Werry, 1999, Anxiolytics, sedatives, and miscellaneous drugs, 433